Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical)

重组抗EGFR人鼠嵌合单克隆抗体（齐鲁制药）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical)
Drug Alias Name重组抗EGFR人鼠嵌合单克隆抗体注射液QL-1105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A